The Situation
____________
An innovative biopharmaceutical company was seeking to partner with a competitive intelligence consultancy that would identify and synthesize current insights to better support its R&D, clinical, and commercial strategies in several areas related to pulmonary diseases. Consequently, the company engaged Sedulo to track competitor and market developments through an annual monitoring program.
The Solution
____________
To ensure the client remained aware of all key developments, Sedulo created an early warning monitoring program:
Ongoing Desk Research: Sedulo’s team proactively tracked competitor and market activities by targeting publicly published information, such as competitor press releases, analyst reports, investor presentations, company websites, industry publications, data publications, earnings, and IR calls.
Primary Research: Sedulo provided a primary research retainer to enable the client to gain deeper insights through direct interviews with key sources as needed throughout the program.
Industry Event Coverage: Sedulo covered select industry events, including AHA, ATS, CHEST, ERS, ESC, EULAR, PVRI, and uILD.
The Success
___________
Sedulo Group captured the competitive landscape in a detailed and executive-ready report, which included key competitors, competitive product profiles, and clinical pipelines by indication. The report was regularly updated with current findings and analysis, ensuring the client remained aware of key developments and their impact.
The areas of focus included:
- Pulmonary Hypertension WHO Groups 1-3
- Systemic Sclerosis ILD (SSc-ILD)
- Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
- Idiopathic Pulmonary Fibrosis (IPF)
The research topics covered:
Clinical Trials (status, timeline, sponsors, patients, endpoints, geographies, data readouts, etc.)
Competitor Profiles (competitor overview, revenue, corporate strategy, product portfolio, development plans, sales strategy, SOV, messaging, etc.)
Product Profiles (development status, MoA, RoA, Dosing, Target Population, milestones and timeline, data summary, implications)
Through this comprehensive monitoring program, the biopharmaceutical company was able to stay ahead of the curve, making informed decisions to support its R&D, clinical, and commercial strategies in the rapidly evolving pulmonary disease landscape.
Sample Reports – All Sources Removed:
